Esophageal cancers comprise adenocarcinoma and squamous cell carcinoma, two distinct
histologic subtypes. Both are difficult to treat and among the deadliest human malignancies …

Personalized cancer therapy applies specific treatments to each patient. Using personalized
tumor models with similar characteristics to the original tumors may result in more accurate …

Patient‐derived cancer cells (PDCs) and patient‐derived xenografts (PDXs) are often used
as tumor models, but have many shortcomings. PDCs not only lack diversity in terms of cell …

Cancer is a major health problem and a leading cause of death worldwide. Early cancer
detection and continuous changes in treatment strategies have improved overall patient …

Establishing a valid in vitro model to represent tumor heterogeneity and biology is critical but
challenging. Tumor organoids are self‐assembled three‐dimensional cell clusters which are …

Current organoid technologies require intensive manual manipulation and lack uniformity in
organoid size and cell composition. We present here an automated organoid platform that …

Modeling the heterogeneity of the tumor microenvironment (TME) in vitro is essential to
investigating fundamental cancer biology and developing novel treatment strategies that …

Translational medicine aims to translate the most promising preclinical research into clinical
practice. Oncology is a continuously growing medical field: the scientific research on cancer …

Purpose: Patient-derived organoids (PDO) are a promising technology to support precision
medicine initiatives for patients with pancreatic ductal adenocarcinoma (PDAC). PDOs may …

Primary tumor organoids are a robust model of individual human cancers and present a
unique platform for patient-specific drug testing. Optical imaging is uniquely suited to assess …